Rapid Involution of Choroidal Metastasis Secondary to Renal Cell Carcinoma With Oral Sunitinib

Oral sunitinib malate (Sutent) is a tyrosine kinase inhibitor that prevents binding of vascular endothelial growth factor and platelet-derived growth factor to their native receptors. It has been approved by the US Food and Drug Administration for the treatment of renal … Continued

Source: JAMA Oncology - October 21, 2014 Category: Cancer & Oncology Authors: Eric K. Chin, MD and colleagues Tags: JAMA Ophthalmology Observation Research Source Type: research